

RESEARCH

Open Access

Small surfactant-like peptides can drive soluble proteins into active aggregates

Bihong Zhou¹, Lei Xing¹, Wei Wu¹, Xian-En Zhang^{2*} and Zhanglin Lin^{1*}

Abstract

Background: Inactive protein inclusion bodies occur commonly in *Escherichia coli* (*E. coli*) cells expressing heterologous proteins. Previously several independent groups have found that active protein aggregates or pseudo inclusion bodies can be induced by a fusion partner such as a cellulose binding domain from *Clostridium cellulovorans* (CBD_{clos}) when expressed in *E. coli*. More recently we further showed that a short amphipathic helical octadecapeptide 18A (EWLKAFYEKVLKELKELF) and a short beta structure peptide ELK16 (LELELKLKLELELKLK) have a similar property.

Results: In this work, we explored a third type of peptides, surfactant-like peptides, for performing such a “pulling-down” function. One or more of three such peptides (L₆KD, L₆K₂, DKL₆) were fused to the carboxyl termini of model proteins including *Aspergillus fumigatus* amadoriase II (AMA, all three peptides were used), *Bacillus subtilis* lipase A (LipA, only L₆KD was used, hereinafter the same), *Bacillus pumilus* xylosidase (XynB), and green fluorescent protein (GFP), and expressed in *E. coli*. All fusions were found to predominantly accumulate in the insoluble fractions, with specific activities ranging from 25% to 92% of the native counterparts. Transmission electron microscopic (TEM) and confocal fluorescence microscopic analyses confirmed the formation of protein aggregates in the cell. Furthermore, binding assays with amyloid-specific dyes (thioflavin T and Cong red) to the AMA-L₆KD aggregate and the TEM analysis of the aggregate following digestion with protease K suggested that the AMA-L₆KD aggregate may contain structures reminiscent of amyloids, including a fibril-like structure core.

Conclusions: This study shows that the surfactant-like peptides L₆KD and its derivatives can act as a pull-down handler for converting soluble proteins into active aggregates, much like 18A and ELK16. These peptide-mediated protein aggregations might have important implications for protein aggregation *in vivo*, and can be explored for production of functional biopolymers with detergent or other interfacial activities.

Keywords: active protein aggregates, amyloid, peptide-mediated protein aggregation, inclusion bodies, fibrillar structure

Background

Inactive inclusion bodies are commonly formed during the overexpression of heterologous proteins in recombinant hosts such as *E. coli* [1]. Only a limited number of them, often small proteins with no or few cysteine residues, can be recovered through refolding [2]. It has been generally accepted that these nonfunctional inclusion bodies are noncrystalline, amorphous structures [3].

One notable exception was the inclusion bodies of beta-galactosidase obtained from overexpression in *E. coli*, which were found to be biologically active [4]. In recent years, however, several groups have strikingly observed the spontaneous formation of pseudo inclusion bodies which are active, when the target proteins are fused to an aggregation-prone domain or peptide [5-7]. For example, D-amino acid oxidase from *Trigonopsis variabilis* (TvDAO) fused with a cellulose binding domain from *Clostridium cellulovorans* (CBD_{clos}) yielded an enzyme aggregate retaining high specific activity [5]. Similarly, MalE31, an aggregation-prone variant of the maltose-binding protein, and a β -amyloid peptide variant A β (F19D) have also been used as fusion partners

* Correspondence: xzhang@wh.iov.cn; zhanglinlin@mails.tsinghua.edu.cn
¹Department of Chemical Engineering, Tsinghua University, One Tsinghua Garden Road, Beijing 100084, China
²State Key Laboratory of Virology, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan 430071, China
Full list of author information is available at the end of the article

for inducing active protein aggregates [6,7]. These domains and peptide presumably provide the specific self-associating modules for the fusion proteins and thus drive the target proteins into aggregates [5].


In our previous studies [8,9], we unexpectedly found that a short amphipathic α helical octadecapeptide 18A (EWLKAFYEKVLKLEKELF) was able to induce several normally soluble proteins into active protein aggregates when expressed in *E. coli*. The fourier transform infrared (FTIR) spectra of the 18A peptide induced protein aggregates revealed enhanced α helical secondary structures, suggesting it was the association of the 18A peptide that led to the formation of pseudo inclusion bodies. Since amphipathic alpha peptides are abundant in protein structures [10], this observation might have implications for protein aggregation in general for biological systems. We subsequently considered whether there were peptides of a different structure other than alpha that could act as a pulling down handler, and a second peptide, ELK16 (LELELKLKLELELKLK) which is beta structure in nature was found to have a similar property [9].

To study the generality of this short-peptide induced protein aggregation, in this work we set out to test a third type of small peptides, i.e., surfactant-like peptides that were designed to mimic surfactants and normally do not resemble either α -helical or β -sheet structure [11,12]. These peptides consist of a hydrophobic tail and a hydrophilic head similar to surfactant molecules, and can spontaneously form nanostructures in aqueous solution. To this end, we attached three of such surfactant-like peptides (L_6KD , L_6K_2 , DKL_6) to the carboxyl termini of model proteins, and expressed the fusions in *E. coli*. Most of the fusion proteins were indeed found to be largely insoluble but retained high biological activity, showing that terminally attached surfactant-like peptides can also drive proteins into biologically active pseudo inclusion bodies in *E. coli*.

Results

Surfactant-like peptides induced proteins to form active protein aggregates


The surfactant-like peptides normally contain a hydrophobic tail and a hydrophilic head. We selected or re-designed three short peptides L_6K_2 , L_6KD , and DKL_6 based on the literature (Figure 1) [11,12]. The hydrophobic moiety of all three peptides is six leucines. Leucine has a large hydrophobic side chain, and can pack with each other more easily than other hydrophobic peptides [11]. The hydrophilic moiety of the molecule is two charged amino acids, the positively charged lysine and/or the negatively charged aspartic acid [11], with a total length of 2-3 nm in the extended conformation [11]. Starting from L_6K_2 , to assess the charge effect, we



replaced one of the lysines with one aspartic acid to yield L_6KD to neutralize the charge, and to assess the positional effect of the hydrophilic head in relation to the model protein, we reversed the sequence of L_6KD to yield DKL_6 . L_6D_2 was not tested as it was reported that L_6K_2 and L_6D_2 showed little difference in terms of self-assembly property [11,12].

These three peptides were first fused to the C-terminus of the model protein *Aspergillus fumigatus* amadoriase II (AMA) via a PT linker PTPPTTPTPPTTPTPTP (Figure 1), and expressed in *E. coli* at 30°C. The expression of these fusion proteins had little effect on the cell growth as judged by OD_{600} measurements. Cells were harvested and lysed, and lysates were separated into soluble and insoluble fractions by centrifugation, and analyzed by SDS-PAGE analyses. Most of the fusion proteins were found in the insoluble fractions, in the range of 64%~77% in terms of mass, markedly different from the native protein (~6%). All three fusion proteins in the insoluble fractions were found to be active. For L_6K_2 fusion, the activity of the insoluble fraction accounted for about 36.8% of the total activity, and for L_6KD and DKL_6 fusions, it was 60.5% (Figure 2A) and 56.1%, respectively. The differences between the mass-based percentages and the activity-based percentages resulted from the different specific activities of the fusion proteins in the soluble and insoluble fractions.

Since AMA- L_6KD fusion protein produced the highest percentage of active aggregate, this suggested that this peptide was more efficient as a “pulling-down” handler, and thus was chosen for further testing using two additional model proteins, *Bacillus subtilis* lipase A (LipA), and *Bacillus pumilus* xylosidase (XynB) (Figure 2B and 2C). In agreement with the above results, both the



LipA-L₆KD and XynB-L₆KD fusion proteins formed obvious active aggregates. For LipA-L₆KD, the insoluble fraction accounted for about 80.2% of the total activity, and for XynB-L₆KD, it was 83.7%. The relative specific activities of the insoluble fractions for three fusions were showed in Table 1. For AMA-L₆KD, it was 92.6% of the native counterpart, and for LipA-L₆KD and XynB-L₆KD, it was 30.2% and 25.6%, respectively.

Microscopic analyses of active protein aggregates

To study the intracellular locations of these pseudo inclusion bodies, transmission electron microscopic (TEM) analyses were performed for recombinant cells expressing the fusion protein AMA-L₆KD. From the TEM images (Figure 3A and 3B), cytoplasmic inclusion bodies were clearly observed for AMA-L₆KD, with the diameters of about several micrometers. Further studies showed that the fusion proteins LipA-L₆KD and XynB-L₆KD had a similar pattern of aggregation (data not shown).

To further confirm the cellular locations of the active protein aggregates, we similarly constructed GFP-L₆KD fusion, and subjected the *E. coli* cells expressing GFP-L₆KD to confocal fluorescence microscopic analyses. As shown in Figure 3C, clearly a localized pattern of fluorescence distribution was observed in the recombinant cells, different from the cells expressing native GFP in which a uniformed distribution of fluorescence was observed [9].

Analyses of amyloid-like properties

Recently, several research groups reported that inclusion bodies formed in *E. coli* may contain amyloid structures [13-16] commonly found in protein deposits associated with diseases such as Alzheimer's disease [17-19]. Amyloids characteristically contain fibril-like cores and bind to specific dyes such as thioflavin T (ThT) and Congo red (CR) [18,20,21]. To gain an insight into the molecular mechanism in the surfactant-like peptide-mediated protein aggregation observed in our study, we thus explored the structural property of AMA-L₆KD aggregate by using thioflavin T and Congo red. Thioflavin T will exhibit a significantly enhanced fluorescence at 480 nm relative to free dye upon binding to amyloid fibrils [21]. As shown in Figure 4, the ThT binding assay for AMA-L₆KD clearly resulted in a 24-fold increase in the fluorescence at 480 nm (Figure 4). The CR binding assay also showed a shift of absorbance maximum to about 508 nm, and a band at about 541 nm in the differential spectrum, characteristic of binding of Congo red to amyloids (data not shown) [20]. We further used TEM coupled with protease K digestion to explore the morphology of the AMA-L₆KD aggregate

Table 1 Enzymatic activities of the fusion proteins produced in *E.coli*

Enzyme	Activity (U/ml) ¹		Percent of activity in insoluble fraction (PDE) ²	Specific activity (U/mg enzyme) ³	Specific activity relative to native enzyme (SArN)
	Soluble fractions	Insoluble fractions			
AMA-native ⁴	734.4 ± 37.5	9.63 ± 2.29	1.3%	1563	100%
AMA-L ₆ KD	236.0 ± 49.0	361.7 ± 59.5	60.5%	1447	92.6%
LipA-native ⁵	20.1 ± 0.5	2.7 ± 0.3	12.0%	96	100%
LipA-L ₆ KD	5.9 ± 0.6	23.8 ± 3.1	80.2%	29	30.2%
XynB-native ⁵	398.8 ± 9.7	136.2 ± 17.0	25.4%	1286	100%
XynB-L ₆ KD	34.0 ± 0.8	174.5 ± 22.9	83.7%	329	25.6%

¹Cells were collected 6 h after IPTG induction. 1 ml soluble enzyme was extracted from 10 OD₆₀₀ of cells; the insoluble fraction was also from 10 OD₆₀₀ of cells and then re-suspended in 1 ml of lysis buffer. Enzymes amounts were calculated based on SDS-PAGE with serial concentrations of BSA as standards. AMA, *Aspergillus fumigatus* amadoriase II; LipA, *Bacillus subtilis* lipase A; XynB, *Bacillus pumilus* β-xylosidase.

²Percentage of the activity found in the insoluble fraction relative to the total activity in the cell lysate (soluble and insoluble fractions combined), also referred to as pulling down efficiency (PDE).

³For the L₆KD fusion, the value concerns the enzyme in the insoluble fraction (more specifically, enzyme aggregate); for the native enzyme, the value concerns the enzyme in the soluble fraction.

⁴Data cited from reference [9].

⁵Data cited from reference [8].


[14,15]. As shown in Figure 5, irregularly organized fibrils can be clearly observed, suggesting an amyloid-like structure for the aggregate.


Discussion

This study demonstrates that terminally attached surfactant-like peptides like L₆KD can convert soluble proteins into active aggregates, with specific activities relative to the native counterparts ranging from 25% to 92%. As aggregation inducers, L₆K₂, L₆KD, DKL₆ are only eight residues in length, even shorter than the peptides 18A (18 residues in length) or ELK16 (16 residues in length). Judging from the activities of the insoluble fractions for

their fusions with AMA as the model protein, it seems that a hydrophilic head with a neutral charge (as in the case of AMA-L₆KD or AMA-DKL₆) is better at promoting active protein aggregation than a hydrophilic head with a charge (as in the case of AMA-L₆K₂). Notably however, the position of the hydrophilic head in relation to the target protein in the fusion, i.e., between the target protein and the hydrophobic tail (as in the case of AMA-DKL₆) or toward the C-terminal end of the hydrophobic tail (as in the case of AMA-L₆KD), makes much less of a difference.

Judging from the microscopic analyses, the morphology of these fusion aggregates is similar to that of those





induced by aggregation-prone domains and peptides as reported earlier [7-9]. While the exact structural detail by which these surfactant-like peptides drive the target proteins into active aggregates remain to be determined, our analysis of the AMA-L₆KD aggregate following digestion of protease K revealed fibril-like structures (Figure 4), and the positive binding assay results with amyloid-specific dyes suggest that the AMA-L₆KD




Figure 5 Fibrillar structure of AMA-L₆KD protein aggregate. The micrograph shows the fibers of AMA-L₆KD aggregate after proteolytic treatment by protease K. Size bar is also shown.

aggregate possesses amyloid-like structures. This is consistent with the view that these pseudo inclusion bodies may contain amyloid-like structures [13-15,17].

Recent studies have shown that, in addition to aggregation-prone domain such as the cellulose binding domain CBD_{clos} [5], several peptides can also induce the formation of protein aggregates or inclusion bodies *in vivo*, such as the human β -amyloid peptide A β 42(F19D) [7], a modified apolipoprotein A-I mimetic amphipathic peptide 18A [8], and the ELK16 peptide derived from EAK16 [9]. These peptides are alpha or beta structure in nature. Our surfactant-like peptides provide a third type of peptide structure beyond alpha or beta that can drive proteins into active aggregates. This peptide-mediated protein aggregation might have important implications for protein aggregation *in vivo*, and for protein aggregation-related diseases. The active protein aggregation induced by these peptides has potential biotechnological applications. For example, it can be used to design a facile expression and purification scheme for protein [22,23], or to obtain active protein aggregates for direct use as biocatalysts [24,25].

Along this line, it is interesting to compare the efficiency of these three short peptides (18A, ELK16 and L₆KD) as aggregation tags, in terms of both pulling down efficiency (PDE) and specific enzyme activity relative to native enzyme (SArN). As shown in Table 2, ELK16 is a better tag for model enzymes AMA and XynB (LipA lost activity when attached to ELK16), compared with 18A and L₆KD. L₆KD is generally comparable with 18A both in terms of PDE and SArN, except that the SArN for LipA-18A fusion aggregate (84%) is much higher than that for LipA-L₆KD (30.2%). It thus seems that L₆KD has no superiority in terms of PDE and SArN compared with ELK16 or 18A, except for its smallest length which in some cases may confer advantage for fusion construction albeit in the cost of pulling down efficiency. Additionally, given its unique surfactant property, it is worthwhile to explore the possible use of this tag for design and mass-production of functional biopolymers with detergent or other interfacial activities via microorganism.

Table 2 Comparison of three different peptides as aggregation tags

Tag	PDE			SArN		
	AMA	LipA	XynB	AMA	LipA	XynB
18A ¹	60.6%	81%	91.3%	88%	84%	21%
ELK16 ²	87.5%	-	94.4%	120%	-	77%
L ₆ KD ³	60.5%	80.2%	83.7%	92.6%	30.2%	25.6%

¹Data cited from reference [8].

²Data cited from reference [9].

³Also see Table 1.

Conclusions

Our study reveals that the presence of surfactant-like peptides can convert fusion proteins into active aggregates *in vivo* which may contain amyloid-like structures. These peptide-mediated protein aggregates may be useful for protein purification, biocatalysis and biosurfactant design and production. Further exploration of this type of protein aggregates may provide new insights into protein aggregation and perhaps related cellular processes and diseases.

Materials and methods

Plasmid construction

To construct plasmid pET30a-AMA-L₆KD, two primers (AMA-up: 5'-TTCTGGACATATGGCGGTAAC-CAAGTCATC-3', AMA-L₆KD-down: 5'-ATGAACTC-GAGTCAATCTTTTCAGCAGCAGCAGCAGCAGCGGCGTCTGGGGTTGGGGTG-3', the restriction sites *NdeI* and *XhoI* were underlined, respectively) were used to amplify the gene encoding AMA-L₆KD from the previously constructed plasmid pET30a-AMA-C18 [8]. Then the amplified DNA fragment was digested with *NdeI* and *XhoI*, and inserted into similarly digested plasmid pET30a (+) (Novagen) to yield pET30a-AMA-L₆KD. Plasmids pET30a-AMA-L₆K₂ and pET30a-AMA-DKL₆ were similarly constructed using primers AMA-L₆K₂-down (5'-ATGAACTCGAGTCATTTTTTTCAGCAGCAGCAGCAGCAGCGGCGTCTGGGGTTGGGGT-3') and AMA-DKL₆-down (5'-ATGAACTCGAGTCACAGCAGCAGCAGCAGCAGTTTTATCCGGCGTCTGGGGTTGGGGTG-3'). Plasmids pET30a-Lip A-L₆KD, pET30a-XynB-L₆KD and pET30a-GFP-L₆KD were obtained by replacing the sequence encoding AMA in pET30a-AMA-L₆KD with that of Lip A, XynB and GFP, respectively.

Expression and extraction of protein aggregates

E. coli BL21 (DE3) (Novagen) was used for all the experiments. The recombinant strains harboring the plasmids were cultured in Luria-Bertani (LB) medium supplemented with 50 mg/l kanamycin at 37°C. Isopropyl β-D-1-thiogalactopyranoside (IPTG, at a final concentration of 0.2 mM) was added to the culture medium at 30°C to induce fusion protein expression, when the cell optical density at 600 nm (OD₆₀₀) reached 0.4-0.6. After 6 h, cells were harvested by centrifugation, and cell pellets were resuspended in lysis buffer (50 mM Tris-HCl, 50 mM NaCl, 5% glycerol, pH 7.2) with a final concentration of 10 OD₆₀₀ per ml. The resuspended cells were lysed by ultrasonication on ice, and the lysates separated by centrifugation. The insoluble fractions were washed twice with 1 ml of lysis buffer, and resuspended again in a same volume of lysis buffer.

The amounts of target proteins in all samples were determined densitometrically by denaturing polyacrylamide gel electrophoresis (SDS PAGE, 12%) using bovine serum albumin (BSA) as standard, followed by staining with Coomassie Brilliant Blue G-250. The values of target protein amounts were calculated with Quantity One software (Bio-Rad Laboratories, Hercules, CA).

Determination of enzyme activities

The enzyme activities in both the soluble and insoluble fractions were assayed with a SPECTRAMAX M2 microplate reader (Molecular Device, CA). The amadoriase activity [26] was measured by monitoring the formation of a quinone dye in a peroxidase-coupling reaction at 555 nm ($\epsilon = 39.2 \text{ cm}^2/\text{mmol}$) at 37°C. 5 ml of enzyme was added to 175 ml of reaction mixture (100 mM potassium phosphate buffer (pH 8.0), 2.7 purpurogallin units of peroxidase, 0.45 mM 4-aminoantipyrine, 0.5 mM N-ethyl-N-(2-hydroxy-3-sulfo-propyl)-m-toluidine (TOOS), and 5.0 mM D-fructosyl-glycine). One unit of amadoriase was defined as the amount of enzyme that produced 1 nmol H₂O₂ per min. LipA activity [27] and XynB activity [28] were measured by monitoring the formation of *p*-nitrophenol at 405 nm ($\epsilon = 18.7 \text{ cm}^2/\text{mmol}$) at 37°C. For lipase, 5 ml of diluted enzyme was added to 175 ml of reaction mixture (50 mM sodium phosphate buffer, pH 8.0; 0.4 mM *p*-nitrophenyl palmitate; 0.2% sodium deoxycholate, and 0.1% gum arabic). For β-xylosidase, 5 ml of enzyme was added to 175 ml of reaction mixture (50 mM phosphate buffer, pH 6.0, 2.5 mM *p*-nitrophenyl β-D-xylopyranoside). One unit of lipase was defined as the amount of enzyme producing 1 μmol of *p*-nitrophenol (pNP) per min while one unit of xylosidase was defined as the amount of enzyme producing 1 nmol of pNP per min.

Laser scanning confocal microscopic (LSCM) analyses

The cells expressing fusion protein GFP-L₆KD were cultivated at 23°C for 22 h after induction with 0.2 mM IPTG. Cells were harvested and washed twice with phosphate buffered saline (PBS). The cell pellets were then fixed with 4% paraformaldehyde and photographed at 488 nm using a Zeiss LSM 710 confocal microscope (Carl Zeiss, Germany).

Transmission electron microscopic (TEM) analyses

TEM was used to analyze the intracellular location and the morphology of protein aggregates. For the intracellular analyses, recombinant cells were harvested after expression 6 h at 30°C and fixed with fixing solution (2.5% glutaraldehyde and 2% osmium tetroxide, dehydrated). The fixed cells were dehydrated through a graded-ethanol serial dehydration step, and embedded

in epoxy resins. The embedded cells were then sectioned into ultrathin slices, stained by stain solution (containing uranyl acetate solution and lead citrate), and observed with a Hitachi H-7650B (Hitachi, Japan) transmission electron microscope at an accelerating voltage of 80 kV. For the morphology analyses [14], extracted protein aggregates were digested with DNase and RNase A (25 µg/ml) for 1 h at 37°C in PBS in the presence of 10 mM MgSO₄. After that, the protein aggregates were washed with 0.5% Triton-X solution and then PBS. The protein aggregates (50 µg/ml) were then digested using protease K (20 µg/ml) at 37°C for 30 min in PBS, and then washed with PBS. The insoluble fractions were resuspended in a same volume of deionized distilled water, and spotted on copper grids for 5 min. The grids were washed with water, and stained with 1% (w/v) aqueous uranyl formate solution. The prepared samples were then analyzed with a Hitachi H-7650B transmission electron microscope at an accelerating voltage of 75 kV.

Binding assays of amyloid-specific dyes to AMA-L₆KD

Thioflavin T (ThT) fluorescence assays were measured with a SPECTRAMAX M2 microplate reader (Molecular Device, CA) with an excitation wavelength of 445 nm and an emission range from 475 nm to 570 nm at 37°C [21,29]. The protein aggregate (in a final concentration of 10 µM) was mixed with 10 µM ThT in PBS in a 96-well black plate. For the Congo red (CR) staining experiment [16,30], 10 µM CR in PBS was incubated in the presence or absence of the protein aggregate (in a final concentration of 10 µM) for 20 min at room temperature and the absorbance spectrum from 360 nm to 700 nm was recorded with a Beckman UV/Vis spectrophotometer.

Acknowledgements

This work was supported by a grant from the National Basic Research Program of China (2009CB724704), and a grant for the National Engineering Lab for Industrial Enzymes from the National Development and Reform commission of China. The authors are grateful to the center of biomedical analysis at Tsinghua University for expert technical assistance with TEM and LSCM analyses.

Author details

¹Department of Chemical Engineering, Tsinghua University, One Tsinghua Garden Road, Beijing 100084, China. ²State Key Laboratory of Virology, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan 430071, China.

Authors' contributions

BZ designed part of the experiments, performed most of the experiments, and prepared the manuscript draft. LX and WW participated in the enzymatic assays and instrumental analyses. ZL and XZ conceived the study, designed and supervised the experiments, and revised the manuscript. All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Received: 12 December 2011 Accepted: 18 January 2012
Published: 18 January 2012

References

1. Marston FAO: The purification of eukaryotic polypeptides synthesized in *Escherichia coli*. *Biochem J* 1986, **240**(1):1-12.
2. Palmer I, Wingfield PT: Preparation and extraction of insoluble (inclusion-body) proteins from *Escherichia coli*. In *Curr Protoc Protein Sci. Volume 6*. Edited by: Coligan JE. Hoboken: John Wiley 2004:6.3.1-6.3.15.
3. Bowden GA, Paredes AM, Georgiou G: Structure and morphology of protein inclusion bodies in *Escherichia coli*. *Nat Biotechnol* 1991, **9**(8):725-730.
4. Worrall DM, Goss NH: The formation of biologically active beta-galactosidase inclusion bodies in *Escherichia coli*. *Aust J Biotechnol* 1989, **3**(1):28-32.
5. Nahalka J, Nidetzky B: Fusion to a pull-down domain: A novel approach of producing *Trigonopsis variabilis* D-amino acid oxidase as insoluble enzyme aggregates. *Biotechnol Bioeng* 2007, **97**(3):454-461.
6. Arie JP, Miot M, Sassoon N, Betton JM: Formation of active inclusion bodies in the periplasm of *Escherichia coli*. *Mol Microbiol* 2006, **62**(2):427-437.
7. Garcia-Fruitos E, Gonzalez-Montalban N, Morell M, Vera A, Ferraz RM, Aris A, Ventura S, Villaverde A: Aggregation as bacterial inclusion bodies does not imply inactivation of enzymes and fluorescent proteins. *Microb Cell Fact* 2005, **4**:27.
8. Wu W, Xing L, Zhou BH, Lin ZL: Assembly of active protein aggregates *in vivo* induced by terminally attached amphipathic peptide. *Biotechnol Adv* .
9. Wu W, Xing L, Zhou BH, Lin ZL: Active protein aggregates induced by terminally attached self-assembling peptide ELK16 in *Escherichia coli*. *Microb Cell Fact* 2011, **10**(1):9.
10. Sharadadevi A, Sivakamasundari C, Nagaraj R: Amphipathic alpha-helices in proteins: Results from analysis of protein structures. *Proteins* 2005, **59**(4):791-801.
11. Vauthey S, Santoso S, Gong HY, Watson N, Zhang SG: Molecular self-assembly of surfactant-like peptides to form nanotubes and nanovesicles. *Proc Natl Acad Sci USA* 2002, **99**(8):5355-5360.
12. von Maltzahn G, Vauthey S, Santoso S, Zhang SU: Positively charged surfactant-like peptides self-assemble into nanostructures. *Langmuir* 2003, **19**(10):4332-4337.
13. Carrio M, Gonzalez-Montalban N, Vera A, Villaverde A, Ventura S: Amyloid-like properties of bacterial inclusion bodies. *J Mol Biol* 2005, **347**(5):1025-1037.
14. Morell M, Bravo R, Espargaro A, Sisquella X, Aviles FX, Fernandez-Busquets X, Ventura S: Inclusion bodies: Specificity in their aggregation process and amyloid-like structure. *Biochim Biophys Acta-Mol Cell Res* 2008, **1783**(10):1815-1825.
15. Wang L, Maji SK, Sawaya MR, Eisenberg D, Riek R: Bacterial inclusion bodies contain amyloid-like structure. *PLoS Biol* 2008, **6**(8):1791-1801.
16. Dasari M, Espargaro A, Sabate R, del Amo JML, Fink U, Grelle G, Bieschke J, Ventura S, Reif B: Bacterial inclusion bodies of Alzheimer's disease beta-Amyloid peptides can be employed to study native-like aggregation intermediate states. *ChemBioChem* 2011, **12**(3):407-423.
17. Mitraki A: Protein aggregation: from inclusion bodies to amyloid and biomaterials. In *Adv Protein Chem Struct Biol. Volume 79*. Edited by: McPherson A. San Diego: Elsevier Academic Press Inc; 2010:89-125.
18. Reinke AA, Gestwicki JE: Insight into amyloid structure using chemical probes. *Chem Biol Drug Des* 2011, **77**(6):399-411.
19. Sabate R, de Groot NS, Ventura S: Protein folding and aggregation in bacteria. *Cell Mol Life Sci* 2010, **67**(16):2695-2715.
20. Howie AJ, Brewer DB: Optical properties of amyloid stained by Congo red: History and mechanisms. *Micron* 2009, **40**(3):285-301.
21. Naiki H, Higuchi K, Hosokawa M, Takeda T: Fluorometric determination of amyloid fibrils *in vitro* using the fluorescent dye, thioflavine T. *Analytical Biochemistry* 1989, **177**(2):244-249.
22. Ge X, Yang DSC, Trabbic-Carlson K, Kim B, Chilkoti A, Filipe CDM: Self-cleavable stimulus responsive tags for protein purification without chromatography. *J Am Chem Soc* 2005, **127**(32):11228-11229.
23. Xing L, Wu W, Zhou BH, Lin ZL: Streamlined protein expression and purification using cleavable self-aggregating tags. *Microb Cell Fact* 2011, **10**:42.

24. Roessler U, Nahalka J, Nidetzky B: Carrier-free immobilized enzymes for biocatalysis. *Biotechnol Lett* 2010, **32**(3):341-350.
25. Sheldon RA: Cross-linked enzyme aggregates as industrial biocatalysts. *Org Process Res Dev* 2011, **15**(1):213-223.
26. Zheng J, Guan H, Xu LH, Yang R, Lin ZL: Engineered amadoriase II exhibiting expanded substrate range. *Appl Microbiol Biotechnol* 2010, **86**(2):607-613.
27. Winkler UK, Stuckmann M: Glycogen, hyaluronate, and some other polysaccharides greatly enhance the formation of exolipase by *Serratia marcescens*. *J Bacteriol* 1979, **138**(3):663-670.
28. Chen TJ, Zhang JQ, Liang L, Yang R, Lin ZL: An *in vivo*, label-free quick assay for xylose transport in *Escherichia coli*. *Anal Biochem* 2009, **390**(1):63-67.
29. Levine H: Thioflavin T interaction with synthetic Alzheimer's disease beta-amyloid peptides: Detection of amyloid aggregation in solution. *Protein Sci* 1993, **2**(3):404-410.
30. Klunk WE, Jacob RF, Mason RP: Quantifying amyloid beta-peptide (A beta) aggregation using the Congo red A beta (CR-A beta) spectrophotometric assay. *Anal Biochem* 1999, **266**(1):66-76.

doi:10.1186/1475-2859-11-10

Cite this article as: Zhou *et al.*: Small surfactant-like peptides can drive soluble proteins into active aggregates. *Microbial Cell Factories* 2012 **11**:10.

**Submit your next manuscript to BioMed Central
and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

